Suppr超能文献

泼尼松龙与倍他米松在类风湿性关节炎中的药理学及临床比较

A pharmacological and clinical comparison of prednisolone and betamethasone in rheumatoid arthritis.

作者信息

Marwah R J, Pickup M E, Al-Shakarchi H, Dixon J S, Lowe J R, Bird H A, Wright V

出版信息

Eur J Clin Pharmacol. 1982 Oct;23(4):321-5. doi: 10.1007/BF00613613.

Abstract
  1. Two oral corticosteroids, prednisolone (8 mg/day) and betamethasone (1 mg/day) have been compared in terms of efficacy and adrenal suppressive activity when used in chronic oral dosage in rheumatoid arthritis. 2. 20 patients were entered to a single blind crossover study receiving each drug for a two-week period. Clinical and laboratory assessments were performed. 3. At this dosage there was no significant difference between any of the clinical parameters assessed for either drug though patient preference was 13 for prednisolone and 7 for betamethasone. 4. At this dosage adrenal suppression was not equivalent, being significantly more marked with betamethasone. 5. The results suggest that prednisolone is the drug of choice for chronic dosage.
摘要
  1. 两种口服皮质类固醇药物,泼尼松龙(8毫克/天)和倍他米松(1毫克/天),在类风湿性关节炎的慢性口服给药中,就疗效和肾上腺抑制活性进行了比较。2. 20名患者进入一项单盲交叉研究,每种药物服用两周。进行了临床和实验室评估。3. 在这个剂量下,两种药物评估的任何临床参数之间没有显著差异,尽管患者对泼尼松龙的偏好为13人,对倍他米松的偏好为7人。4. 在这个剂量下,肾上腺抑制并不相同,倍他米松的抑制作用明显更强。5. 结果表明,泼尼松龙是慢性给药的首选药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验